Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL11753083 | 0.98 | CYP1A2 (0.60) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL6859262 | 0.84 | CYP1A2 (0.64) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL10458447 | 0.84 | KDM4E (0.72) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL5113547 | 0.84 | MAPT (0.49) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL1226530 | 0.83 | SMN1; SMN2 (0.54) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL29519193 | 0.83 | SMN1; SMN2 (0.54) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8645476 | 0.83 | GPR35 (0.68) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL665304 | 0.83 | MEN1 (0.69) | HPGDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2097649 | 0.82 | CYP1A2 (0.62) | CYP1A2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL2175829 | 0.82 | CYP1A2 (0.75) | CYP1A2HPGDCYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3011835-B1 | Method for anti-sprouting tuber treatment with reduced amount of CIPC | ARYSTA LIFESCIENCE BENELUX SPRL (BE) | 2020-04-08 | — | — | EP | claimed |
| EP-2307024-B1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-01-09 | — | — | EP | claimed |
| US-7655801-B2 | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-02 | — | — | US | claimed |
| EP-0820281-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES AND N-CHLOROPHENYLTHIOCARBAMATES FOR INHIBITING THE GROWTH OF VIRUSES | UAF TECHNOLOGIES AND RES LLC (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060142335-A1 | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2006-06-29 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20030149088-A1 | HIV treatment | UNIVERSITY OF ARIZONA FOUNDATION (US) | 2003-08-07 | — | — | US | claimed |
| US-6498188-B1 | ADMINISTRATING AN N-CHLOROPHENYLCARBAMATE OR AN N-CHLORO-PHENYLTHIOCARBAMATE IN COMBINATION WITH POTENTIATOR AND/OR CHEMOTHERAPEUTIC AGENT | THE PROCTER & GAMBLE COMPANY | 2002-12-24 | — | — | US | claimed |
| WO-2002041891-A2 | HIV TREATMENT WITH BENZIMIDAZOLES | THE PROCTER & GAMBLE COMPANY (US) | 2002-05-30 | — | — | WO | claimed |
| US-20010041678-A1 | Compositions and methods for treating cancer | THE PROCTER & GAMBLE COMPANY | 2001-11-15 | — | — | US | claimed |
| US-6251870-B1 | COMPRISING A CHEMOTHERAPEUTIC AGENT SUCH AS METHOTREXATE AND AN N-CHLOROPHENYLCARBAMATE OR N-CHLOROPHENYLTHIOCARBAMATE OF GIVEN FORMULA | THE PROCTER & GAMBLE COMPANY | 2001-06-26 | — | — | US | claimed |
| US-20010002403-A1 | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions | THE PROCTER & GAMBLE COMPANY | 2001-05-31 | — | — | US | claimed |
| US-6177460-B1 | USING A N-CHLOROPHENYL(THIO)CARBAMATE | THE PROCTER & GAMBLE COMPANY | 2001-01-23 | — | — | US | claimed |
| US-5932609-A | Pharmaceutical composition for inhibiting the growth of cancers | THE PROCTER & GAMBLE COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| US-5932604-A | Pharmaceutical compositions for the treatment of viral infections | THE PROCTER & GAMBLE COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| EP-0820282-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES, N-CHLOROPHENYLTHIOCARBAMATES AND N-PHOSPHONOGLYCINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCERS AND VIRUSES IN MAMMALS | THE PROCTER & GAMBLE COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| EP-0820281-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES AND N-CHLOROPHENYLTHIOCARBAMATES FOR INHIBITING THE GROWTH OF VIRUSES AND CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| WO-1996032103-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES, N-CHLOROPHENYLTHIOCARBAMATES AND N-PHOSPHONOGLYCINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCERS AND VIRUSES IN MAMMALS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-17 | — | — | WO | claimed |
| WO-1996032104-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING N-CHLOROPHENYLCARBAMATES AND N-CHLOROPHENYLTHIOCARBAMATES FOR INHIBITING THE GROWTH OF VIRUSES AND CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CYP1A2 48/4885HPGD 66/4885CYP2C19 89/4885 |
| US-20030149088-A1 | HIV treatment | BCOR, CYP3A4, NNT | CYP1A2 267/4885HPGD 1595/4885CYP2C19 113/4885 |
| US-20010002403-A1 | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions | TP53, CPS1, MGMT | CYP1A2 4552/4885HPGD 1950/4885CYP2C19 3246/4885 |
| US-20010041678-A1 | Compositions and methods for treating cancer | HCCS, NTPCR, HMBS | CYP1A2 3187/4885HPGD 1742/4885CYP2C19 1443/4885 |
| US-20060142335-A1 | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors | ACHE, BCHE, NAAA | CYP1A2 362/4885HPGD 2135/4885CYP2C19 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.